Overview Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Sign: Together with chemotherapy, to the therapy of adult clients with locally recurrent unresectable or metastatic triple-negative breast most cancers that have not received prior chemotherapy for metastatic ailment and whose tumours express programmed cell death-ligand one (mixed good score ≥ ten) as based https://clarenced570cfj6.targetblogs.com/profile